Stryker Co. (NYSE:SYK) Shares Purchased by Signature Estate & Investment Advisors LLC

Signature Estate & Investment Advisors LLC raised its position in Stryker Co. (NYSE:SYK) by 3.9% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,459 shares of the medical technology company’s stock after buying an additional 55 shares during the quarter. Signature Estate & Investment Advisors LLC’s holdings in Stryker were worth $527,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of SYK. Centennial Bank AR boosted its stake in shares of Stryker by 106.7% during the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after purchasing an additional 48 shares during the last quarter. Hara Capital LLC purchased a new position in shares of Stryker during the third quarter valued at approximately $42,000. HBW Advisory Services LLC acquired a new stake in Stryker during the third quarter worth approximately $42,000. Grove Bank & Trust grew its stake in Stryker by 84.8% in the 3rd quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock worth $44,000 after acquiring an additional 56 shares during the period. Finally, DT Investment Partners LLC lifted its stake in shares of Stryker by 114.3% during the 3rd quarter. DT Investment Partners LLC now owns 135 shares of the medical technology company’s stock worth $49,000 after purchasing an additional 72 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on SYK shares. Piper Sandler reaffirmed an “overweight” rating and issued a $420.00 price objective (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. BTIG Research lifted their price target on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Citigroup raised their target price on shares of Stryker from $406.00 to $411.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Royal Bank of Canada upped their price target on shares of Stryker from $386.00 to $400.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Finally, Wolfe Research assumed coverage on shares of Stryker in a report on Tuesday, September 10th. They issued an “outperform” rating and a $405.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $393.65.

Stryker Stock Up 1.8 %

Shares of NYSE:SYK opened at $390.08 on Friday. The company has a market capitalization of $148.71 billion, a price-to-earnings ratio of 41.81, a price-to-earnings-growth ratio of 2.94 and a beta of 0.91. The company has a 50 day moving average of $364.07 and a two-hundred day moving average of $347.40. Stryker Co. has a 52-week low of $282.35 and a 52-week high of $392.70. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. The business had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business’s revenue was up 11.9% on a year-over-year basis. During the same period last year, the business earned $2.46 EPS. As a group, analysts forecast that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Insider Activity at Stryker

In other news, VP M Kathryn Fink sold 2,121 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $370.00, for a total value of $784,770.00. Following the sale, the vice president now owns 10,042 shares in the company, valued at approximately $3,715,540. This represents a 17.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Viju Menon sold 600 shares of Stryker stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the transaction, the insider now owns 9,069 shares of the company’s stock, valued at $3,219,495. This trade represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 67,381 shares of company stock valued at $24,825,275. Insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.